<DOC>
	<DOCNO>NCT00140400</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy prime-boost dose schedule Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine ( Allogeneic Prostate GVAX® ) measure standard toxicity evaluation , change PSA , tumor response . Additional objectives measure time PSA and/or clinical disease progression well local systemic immune response vaccine .</brief_summary>
	<brief_title>Prime-Boost Dose Scheduling Trial Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine ( Allogeneic Prostate GVAX® ) Patients With Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Diagnosis adenocarcinoma prostate cancer Prostate cancer deem unresponsive refractory hormone therapy An ECOG performance status 0 1 Transitional cell , small cell , neuroendocrine , squamous cell prostate cancer Previous chemotherapy , biological immunotherapy cancer Previous gene therapy cancer Significant cancer relate pain</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Advanced prostate cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Hormone-refractory</keyword>
	<keyword>GVAX</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Allogeneic cell</keyword>
</DOC>